tirzepatide + bpc-157 side effects Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring Q&A: Understanding the Pharmaceutical Community's

Lyon C, Langner S

7(1): p

PharmaTher announced on February 2, 2026 a strategic initiative to pursue Health Canada approval for generic semaglutide, targeting broad dose coverage from 0.25 mg to 2.4 mg [Source: glp1prices.ca/generic-alert]

Blockade of IDO-kynurenine-ahR axis ameliorated colitis-associated colon cancer via inhibiting immune tolerance

in vitro and animal studies have linked thymosin beta-4 overexpression to increased tumor size and metastasis in several cancer types (including colorectal and pancreatic cancer), leading researchers to flag a theoretical cancer-promotion risk, particularly for anyone with an active malignancy or recent cancer history Self-reported effects compiled from user and case reports, not controlled trials, include injection-site redness or itching, transient fatigue, and headache